Skip to main content
NCBI home page
The British Journal of Cancer. Supplement logoLink to The British Journal of Cancer. Supplement
. 1992 Aug;18:S63–S67.

Acute myelogenous leukaemia in children under 2 years--experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group.

J Vormoor 1, J Ritter 1, U Creutzig 1, J Boos 1, P Heyen 1, W D Ludwig 1, J Harbott 1, H Löffler 1, G Schellong 1
PMCID: PMC2149667  PMID: 1503929

Abstract

Clinical, morphological, immunological, cytogenetical and prognostic features of 84 children under 2 years of age with AML in studies AML-BFM-78, -83 and -87 were retrospectively analysed. There was a high incidence of acute monoblastic leukaemia (FAB M5) (41 patients--49%) and acute megakaryoblastic leukaemia (FAB M7) (study AML-BFM-87: five patients--13%) in this age group. Acute monoblastic leukaemia was associated with hepatosplenomegaly, extramedullary organ manifestations and chromosomal abnormalities involving 11q23. The probability of an 11-year event-free survival of all patients under 2 years of the three studies combined was 39% (SD 6%). While the event-free survival rates of patients aged 2 years and older could be improved in studies AML-BFM-83 and -87 compared with study AML-BFM-78, overall prognosis in children under 2 years in the three consecutive studies remained unchanged. The event-free survival rate of children with acute monoblastic leukaemia in both age groups was comparable (7 yr-EFS (AML-BFM-83 and -87): much less than 2 years--43% (SD 9%), =/much greater than 2 years--33% (SD 9%); P much greater than 0.5). This also applied to other risk groups. In conclusion, taking the high incidence of acute monoblastic and megakaryoblastic leukaemia in children under 2 years into account, no significant differences between children under 2 years or older children concerning response to therapy and overall prognosis could be evaluated.

Full text

PDF
S63

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman A. J. Clinical features and biological implications of acute mixed lineage (hybrid) leukemias. Am J Pediatr Hematol Oncol. 1990 Summer;12(2):123–133. [PubMed] [Google Scholar]
  2. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med. 1985 Sep;103(3):460–462. doi: 10.7326/0003-4819-103-3-460. [DOI] [PubMed] [Google Scholar]
  3. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976 Aug;33(4):451–458. doi: 10.1111/j.1365-2141.1976.tb03563.x. [DOI] [PubMed] [Google Scholar]
  4. Borowitz M. J., Gockerman J. P., Moore J. O., Civin C. I., Page S. O., Robertson J., Bigner S. H. Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia. Am J Clin Pathol. 1989 Mar;91(3):265–270. doi: 10.1093/ajcp/91.3.265. [DOI] [PubMed] [Google Scholar]
  5. Creutzig U., Ritter J., Riehm H., Langermann H. J., Henze G., Kabisch H., Niethammer D., Jürgens H., Stollmann B., Lasson U. Improved treatment results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78. Blood. 1985 Feb;65(2):298–304. [PubMed] [Google Scholar]
  6. Creutzig U., Ritter J., Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood. 1990 May 15;75(10):1932–1940. [PubMed] [Google Scholar]
  7. Darbyshire P. J., Smith J. H., Oakhill A., Mott M. G. Monocytic leukemia in infancy. A review of eight children. Cancer. 1985 Oct 1;56(7):1584–1589. doi: 10.1002/1097-0142(19851001)56:7<1584::aid-cncr2820560720>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  8. Fong C. T., Brodeur G. M. Down's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. Cancer Genet Cytogenet. 1987 Sep;28(1):55–76. doi: 10.1016/0165-4608(87)90354-2. [DOI] [PubMed] [Google Scholar]
  9. Hirt A., Luethy A. R., Mueller B., Gugler E., Wagner H. P. Acute megakaryoblastic leukemia in children identified by immunological marker studies. Am J Pediatr Hematol Oncol. 1990 Spring;12(1):27–33. doi: 10.1097/00043426-199021000-00006. [DOI] [PubMed] [Google Scholar]
  10. Köller U., Haas O. A., Ludwig W. D., Bartram C. R., Harbott J., Panzer-Grümayer R., Hansen-Hagge T., Ritter J., Creutzig U., Knapp W. Phenotypic and genotypic heterogeneity in infant acute leukemia. II. Acute nonlymphoblastic leukemia. Leukemia. 1989 Oct;3(10):708–714. [PubMed] [Google Scholar]
  11. Lee E. J., Pollak A., Leavitt R. D., Testa J. R., Schiffer C. A. Minimally differentiated acute nonlymphocytic leukemia: a distinct entity. Blood. 1987 Nov;70(5):1400–1406. [PubMed] [Google Scholar]
  12. Levitt G. A., Stiller C. A., Chessells J. M. Prognosis of Down's syndrome with acute leukaemia. Arch Dis Child. 1990 Feb;65(2):212–216. doi: 10.1136/adc.65.2.212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lie S. O. Acute myelogenous leukaemia in children. Eur J Pediatr. 1989 Feb;148(5):382–388. doi: 10.1007/BF00595892. [DOI] [PubMed] [Google Scholar]
  14. Ludwig W. D., Bartram C. R., Harbott J., Köller U., Haas O. A., Hansen-Hagge T., Heil G., Seibt-Jung H., Teichmann J. V., Ritter J. Phenotypic and genotypic heterogeneity in infant acute leukemia. I. Acute lymphoblastic leukemia. Leukemia. 1989 Jun;3(6):431–439. [PubMed] [Google Scholar]
  15. Peeters M., Poon A. Down syndrome and leukemia: unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr. 1987 Jul;146(4):416–422. doi: 10.1007/BF00444952. [DOI] [PubMed] [Google Scholar]
  16. Peto R., Pike M. C. Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics. 1973 Sep;29(3):579–584. [PubMed] [Google Scholar]
  17. Pui C. H., Kalwinsky D. K., Schell M. J., Mason C. A., Mirro J., Jr, Dahl G. V. Acute nonlymphoblastic leukemia in infants: clinical presentation and outcome. J Clin Oncol. 1988 Jun;6(6):1008–1013. doi: 10.1200/JCO.1988.6.6.1008. [DOI] [PubMed] [Google Scholar]
  18. Schellong G., Creutzig U., Ritter J. Treatment of acute myelogenous leukemia in children. Med Oncol Tumor Pharmacother. 1985;2(1):17–25. doi: 10.1007/BF02934776. [DOI] [PubMed] [Google Scholar]
  19. Windebank K. P., Tefferi A., Smithson W. A., Li C. Y., Solberg L. A., Jr, Priest J. R., Elliott S. C., de Alarcon P. A., Weinblatt M. E., Burgert E. O., Jr Acute megakaryocytic leukemia (M7) in children. Mayo Clin Proc. 1989 Nov;64(11):1339–1351. doi: 10.1016/s0025-6196(12)65376-2. [DOI] [PubMed] [Google Scholar]
  20. van Wering E. R., Kamps W. A. Acute leukemia in infants. A unique pattern of acute nonlymphocytic leukemia. Am J Pediatr Hematol Oncol. 1986 Fall;8(3):220–224. doi: 10.1097/00043426-198623000-00008. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Cancer. Supplement are provided here courtesy of Cancer Research UK

RESOURCES